Israel Institute for Biological Research (IIBR), an institute run by Israel’s Defense Ministry, has signed a memorandum of understanding (MoU) with the NRx Pharmaceuticals. According to which Israel’s domestic COVID-19 vaccine will undergo clinical trials as revealed by a statement.
Brilife, the said vaccine, will be driven to complete its third-stage clinical trials by the NRx Pharmaceuticals. Tens of thousands of volunteers belonging to Ukraine, Georgia and Israel will take part for the said cause after which the company will work up the commercialization of the vaccine. The Israeli vaccine is currently undergoing its second-stage trials after the fruitful attainment of first one in December, 2020 by IIBR.
The Defense Minister of Israel, Benny Gantz, applauded this covenant considering it “an excellent news”. In one of his statements Gantz narrates, “I anticipate that with this agreement, we will be able to complete the development of the vaccine and enable Israel to produce vaccines independently, because as we have seen recently – the coronavirus is not going anywhere”.
